Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the study is to evaluate the synergistic effects of daily consumption of food products fortified with bioactive components (fibres, polyphenols, omega-3, Slow Digestible Starch) for 9 weeks, compared to the daily intake of standard food products on low-grade inflammation in cardiometabolic risk subject.
The inflammatory parameters will be assessed in fasting and in postprandial period after the consumption of a hyper-carbohydrate and hyper-lipidic test meal called Flexmeal. A metabolic stress will be induced by a fructose ingestion challenge during the last 6 days of interventional period.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| bioactive components fortified food products | Experimental |
| |
| control food products | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| bioactive components fortified food products intake (biscuits and cookies) | Other | Volunteers will have to consume daily 100 g of fortified biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass) |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline postprandial plasma endotoxemia binding protein kinetics: LBP (lipopolysaccharide-binding protein) and CD14 (Cluster of differentiation 14) | LBP and CD14 proteins will be measured at time 0, 120 and 300 after test meal intake | baseline, 8 and 9 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline fasting and postprandial plasma inflammatory markers: MCP-1, RANTES, IFNγ, IL-6, TNF-α, IL-1β, CRPus, adiponectin | MCP-1 ( monocyte chemotactic protein-1), RANTES (Regulated on activation, normal T expressed and secreted), IFNγ (Interferon γ) , IL-6 (Interleukin 6), TNF-α (Tumor Necrosis Factor α), IL-1β (Interleukin 1β), CRPus, adiponectin will be measured at time 0 and 300 minutes after test meal intake |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Martine LAVILLE, Pr | Centre de Recherche en Nutrition Humaine Rhone-Alpe | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre de Recherche en Nutrition Humaine Rhône-Alpes | Pierre-Bénite | 69310 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39710576 | Result | Hornero-Ramirez H, Morisette A, Marcotte B, Penhoat A, Lecomte B, Panthu B, Lessard Lord J, Thirion F, Van-Den-Berghe L, Blond E, Simon C, Caussy C, Feugier N, Dore J, Sanoner P, Meynier A, Desjardins Y, Pilon G, Marette A, Cani PD, Laville M, Vinoy S, Michalski MC, Nazare JA. Multifunctional dietary approach reduces intestinal inflammation in relation with changes in gut microbiota composition in subjects at cardiometabolic risk: the SINFONI project. Gut Microbes. 2025 Dec;17(1):2438823. doi: 10.1080/19490976.2024.2438823. Epub 2024 Dec 22. | |
| 37892479 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| control food products intake (biscuits and cookies) | Other | Volunteers will have to consume daily 100 g of standard biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass) |
|
| baseline, 8 and 9 weeks |
| Change of fasting and postprandial plasma inflammatory endotoxemia LPS (lipopolysaccharide) | LPS will be measured at time 0, 60, 120, 180, 240, 300 after test meal intake | baseline, 8 and 9 weeks |
| Change from baseline fasting and postprandial plasma endothelial function markers: Human CVD Panel 2, Lipocalin-2/NGAL, Myeloperoxidase, sICAM-1, sVCAM-1, ADAMTS13, D-dimer, GDF-15, Myoglobin, sP-Selectin, Serum Amyloid A | Human CVD Panel 2, Lipocalin-2/NGAL (neutrophil gelatinase-associated lipocalin), Myeloperoxidase, sICAM-1(Soluble Inter-cellular Adhesion Molecule-1), sVCAM-1(Soluble Form of Vascular Cell Adhesion Molecule 1), ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), D-dimer, GDF-15 (Growth differentiation factor 15), Myoglobin, sP-Selectin, Serum Amyloid A will be measured at time 0 and 300 minutes after test meal intake | baseline, 8 and 9 weeks |
| Change from baseline fasting plasma oxidative stress parameters: GSH, GSSG, Glutathion peroxidase/ reductase activity, MDA | GSH (glutathione), GSSG (glutathione disulfide), Glutathion peroxidase/ reductase activity will be measured at time 0 and MDA (malondialdehyde) will be measured at 0 and 300 minutes after test meal intake | baseline, 8 and 9 weeks |
| Change from baseline body composition | Body composition will be measured by BodPod technique | baseline, 8 and 9 weeks |
| Change from baseline plasma metabolites and hormone kinetics : glucose, insulin, triglycerides, non-esterified fatty acids | Plasma metabolites and hormone will be measured at time -30, 0, 15, 30, 45, 60, 90, 120, 180, 240, 300 minutes after test meal intake | baseline, 8 and 9 weeks |
| Change from baseline fasting plasma lipids : total cholesterol , HDL cholesterol, LDL cholesterol, triglycerides, non-esterified fatty acids | fasting plasma lipids will be measured before test meal ingestion | baseline, 8 and 9 weeks |
| Change from baseline resting energy expenditure | resting metabolic rate will be measured by indirect calorimetry | baseline, 8 and 9 weeks |
| Change from baseline substrates oxidation | substrates oxidation will be measured by indirect calorimetry after test meal intake during five hours. | baseline, 8 and 9 weeks |
| Change from baseline gut microbiota composition | gut microbiota composition will be measured by 16S RNA (ribonucleic acid) analysis | baseline, 8 weeks |
| Change from baseline stool consistency | stool consistency will be measured by Bristol scale and every week during the interventional period | nine weeks |
| Change from baseline stool frequency | stool frequency will be measured by questionnaire at baseline and every week during the interventional period | nine weeks |
| Change from baseline tolerance gastro-intestinal symptoms like bloating ,abdominal rumbling ,flatulence ,abdominal pain, nausea, vomiting | Gastro intestinal symptoms will be collected by questionnaires and visual analogue scale (VAS) score (on a 90mm horizontal line; from no symptom (minimal) to serious symptom (maximum)) at baseline and every week during the interventional period | nine weeks |
| Change from baseline diet intake | diet intake will be evaluated by a three days diet survey | baseline, 8 and 9 weeks |
| Change from baseline fasting plasma zonulin | comparison of fasting plasma zonulin from baseline | baseline, 8 and 9 weeks |
| Change from baseline polyphenols urinary concentrations | Comparison of polyphenols urinary concentrations from baseline | baseline, 8 weeks |
| Result |
| Demangeat A, Hornero-Ramirez H, Meynier A, Sanoner P, Atkinson FS, Nazare JA, Vinoy S. Complementary Nutritional Improvements of Cereal-Based Products to Reduce Postprandial Glycemic Response. Nutrients. 2023 Oct 17;15(20):4401. doi: 10.3390/nu15204401. |
| ID | Term |
|---|---|
| D056128 | Obesity, Abdominal |
| D007249 | Inflammation |
| D019446 | Endotoxemia |
| ID | Term |
|---|---|
| D009765 | Obesity |
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010335 | Pathologic Processes |
| D016470 | Bacteremia |
| D018805 | Sepsis |
| D007239 | Infections |
| D014115 | Toxemia |
| D018746 | Systemic Inflammatory Response Syndrome |
Not provided
Not provided